EssilorLuxottica: First-half 2019 results – Combination at work and acceleration of the integration process – Strong free cash flow

by NASDAQ Market News July 31, 2019

NASDAQ Market News
Click here to email author

New number of shares and votes in Oasmia Pharmaceutical AB (publ)

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)

Ads